News about AbbVie
AbbVie and Alector hope to apply immunotherapy to dementia and Alzheimer's.
Stocks are flourishing and IPOs abound.
AbbVie's victory is bad news for rival biotech giant Gilead.
If he pulls it off, he will make more than all of his peers combined.
A government watchdog will probe the orphan drug program.